Table 2.

Effect of Ang II on the lifetime of AT₁R-EGFP in AT₁R-HEK293 cells. Cells were treated with Ang II (100 nM) at the indicated time periods and fixed, as described in Section 2. Data are mean±S.E.; N, number of cells analyzed; ANOVA, Student-Newman-Keuls test.

Donor	Acceptor	N	Pretreatment	Ang II (min)	AT1R lifetime τm (ns)
AT1R- EGFP	Alexa 555 alone	7	None	0	2.33±0.04
		5		5	2.31±0.11
		5		30	2.32±0.08
AT1R- EGFP	Rab5- Alexa 555	16	None	0	2.01±0.10a
		12		5	1.78±0.31a b, b
		36		30	1.56±0.41a b c, 2n2, c
AT1R- EGFP	Rab7- Alexa 555	25	None	0	2.11±0.11
		11		5	2.09±0.37
		26		30	1.81±0.09a b c, 2n2, c
AT1R- EGFP	Rab5- Alexa 555	15	Latrunculin A	0	2.35±0.23
		21		5	2.36±0.29
		13		30	2.41±0.34
AT1R- EGFP	Rab7- Alexa 555	18	Latrunculin A	0	2.38±0.33
		17		5	2.46±0.38
		16		30	2.55±0.41
AT1R- EGFP	Rab5- Alexa 555	12	Nocodazole	0	2.18±0.13
		22		5	1.69±0.34a b, b
		23		30	1.60±0.21a b c, 2n2, c
AT1R- EGFP	Rab7- Alexa 555	15	Nocodazole	0	2.41±0.51
		16		5	2.39±0.43
		24		30	1.73±0.17a b c, 2n2, c

^aP<0.05 versus Alexa 555 alone as the acceptor, Ang II-0 min treatment.

^bP<0.05 versus Ang II-0 min treatment.

^cP<0.05 versus Ang II 5 min treatment.